EcoDrugPlus

Neuropeptide Y Receptor Type 4

Ensembl ID : ENSBBBG00000010248
Gene Symbol: LOC104998993
2 Cross references
116 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSBBBG00000017290
Gene Symbol: NTSR1
3 Cross references
208 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSBBBG00000004133
Gene Symbol: NTRK1
3 Cross references
200 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSBBBG00000012750
Gene Symbol: NTRK2
3 Cross references
288 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSBBBG00000023291
Gene Symbol: NTRK3
3 Cross references
271 Possible Orthologues:

Nicastrin

Ensembl ID : ENSBBBG00000020706
Gene Symbol: NCSTN
3 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSBBBG00000001300
Gene Symbol: NAMPT
3 Cross references
235 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSBBBG00000018223
Gene Symbol: NOS2
3 Cross references
166 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSBBBG00000018967
Gene Symbol: NOTCH3
3 Cross references
201 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSBBBG00000023074
Gene Symbol: NFKB1
3 Cross references
205 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSBBBG00000005894
Gene Symbol: NFKB2
3 Cross references
124 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSBBBG00000009696
Gene Symbol: NR1H2
3 Cross references
303 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).